Pfiz­er stops one of two Phase 3 tri­als for sick­le cell drug, still plans to seek ap­proval in 2026

Pfiz­er ter­mi­nat­ed one of two late-stage tri­als for a sick­le cell treat­ment can­di­date from its $5.4 bil­lion ac­qui­si­tion of Glob­al Blood Ther­a­peu­tics in 2022.

The phar­ma gi­ant is still run­ning a sec­ond Phase 3 for the drug, known as in­clacum­ab, a spokesper­son con­firmed Tues­day to End­points News.

A Mon­day up­date to the fed­er­al clin­i­cal tri­als data­base shows that Pfiz­er end­ed a Phase 3 of in­clacum­ab due to “poor ac­cru­al and as­so­ci­at­ed [re­cruit­ment] chal­lenges.” The study en­rolled 72 peo­ple out of an orig­i­nal­ly planned 280, ac­cord­ing to clin­i­cal­tri­als.gov.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER